Inhibikase Therapeutics, Inc. Common Stock IKT
$1.63
-1.81%
at last close
Financials (TTM)
- Revenue
- $3.72 million
- Net Income
- $-50,961,294
- Net Margin
- -1371.74%
- Return on Equity
- -30.40%
- Debt-to-Equity
- —
- P/E Ratio
- —
- Price / Book
- 1.31
- Price / Sales
- 59.00
Over the trailing twelve months, Inhibikase Therapeutics, Inc. Common Stock generated revenue of $3.72 million and net income of $-50,961,294, a net margin of -1371.74%.
At the last closing price of $1.63, IKT trades at 59.00 times sales, with a market capitalization of $219.17 million.
Key Stats
- Last Close
- $1.63
- Market Cap
- $219.17 million
- 52-Week Range
- $1.33 – $2.37
- Average Volume
- 671K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.